| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $29,943 | 1 | 8 |
Sells | $16,968,897 | 11 | 92 |
| Rouan Sarah Kathryn | director | 1 | $29,943 | 0 | $0 | $29,943 |
| FOEHR MATTHEW W | director | 0 | $0 | 1 | $561,694 | $-561,694 |
| Rowland Charles A Jr | director | 0 | $0 | 1 | $2.13M | $-2.13M |
| ZANTE GREG | Chief Financial Officer | 0 | $0 | 3 | $2.23M | $-2.23M |
| Mancini Marianna | Chief Operating Officer | 0 | $0 | 3 | $2.24M | $-2.24M |
| Lian Brian | President & CEO | 0 | $0 | 3 | $9.8M | $-9.8M |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Viking Therapeutics, Inc. have bought $29,943 and sold $16.97M worth of Viking Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Viking Therapeutics, Inc. have bought $159,978 and sold $45.78M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rouan Sarah Kathryn (director) — $29,943.
The last purchase of 1,240 shares for transaction amount of $29,943 was made by Rouan Sarah Kathryn (director) on 2025‑03‑31.
| 2026-01-05 | Sale | Lian Brian | President & CEO | 233,409 0.2117% | $32.96 | $7.69M | -2.30% | |
| 2026-01-05 | Sale | Mancini Marianna | Chief Operating Officer | 57,661 0.0523% | $32.98 | $1.9M | -2.30% | |
| 2026-01-05 | Sale | ZANTE GREG | Chief Financial Officer | 57,661 0.0522% | $32.90 | $1.9M | -2.30% | |
| 2026-01-02 | Sale | FOEHR MATTHEW W | director | 16,000 0.0141% | $35.11 | $561,694 | -11.00% | |
| 2025-10-28 | Sale | Lian Brian | President & CEO | 38,989 0.0358% | $35.01 | $1.36M | -0.80% | |
| 2025-10-28 | Sale | Mancini Marianna | Chief Operating Officer | 6,185 0.0057% | $35.00 | $216,492 | -0.80% | |
| 2025-10-28 | Sale | ZANTE GREG | Chief Financial Officer | 6,185 0.0057% | $35.00 | $216,481 | -0.80% | |
| 2025-10-27 | Sale | Rowland Charles A Jr | director | 60,000 0.056% | $35.57 | $2.13M | -3.17% | |
| 2025-07-03 | Sale | Lian Brian | President & CEO | 26,889 0.0237% | $27.80 | $747,633 | +16.87% | |
| 2025-07-03 | Sale | Mancini Marianna | Chief Operating Officer | 4,266 0.0037% | $27.77 | $118,473 | +16.87% | |
| 2025-07-03 | Sale | ZANTE GREG | Chief Financial Officer | 4,266 0.0037% | $27.76 | $118,428 | +16.87% | |
| 2025-03-31 | Rouan Sarah Kathryn | director | 1,240 0.0011% | $24.15 | $29,943 | +25.22% | ||
| 2025-01-06 | Sale | Lian Brian | President & CEO | 194,490 0.1752% | $42.75 | $8.31M | -29.98% | |
| 2025-01-06 | Sale | Mancini Marianna | Chief Operating Officer | 54,215 0.0488% | $42.75 | $2.32M | -29.98% | |
| 2025-01-06 | Sale | ZANTE GREG | Chief Financial Officer | 50,309 0.0453% | $42.75 | $2.15M | -29.98% | |
| 2024-11-08 | Sale | MACARTNEY LAWSON | director | 2,000 0.0018% | $68.67 | $137,333 | -56.59% | |
| 2024-10-28 | Sale | ZANTE GREG | Chief Financial Officer | 131,687 0.1468% | $76.61 | $10.09M | -60.04% | |
| 2024-10-25 | Sale | SINGLETON J MATTHEW | director | 16,000 0.0185% | $79.50 | $1.27M | -61.90% | |
| 2024-10-25 | Sale | Rouan Sarah Kathryn | director | 11,000 0.0129% | $80.89 | $889,790 | -61.90% | |
| 2024-09-20 | Sale | Lian Brian | President & CEO | 216,130 0.1961% | $70.83 | $15.31M | -55.85% |
| Lian Brian | President & CEO | 2499291 2.1629% | $76.1M | 0 | 19 | |
| Mancini Marianna | Chief Operating Officer | 409190 0.3541% | $12.46M | 0 | 9 | |
| ZANTE GREG | Chief Financial Officer | 189891 0.1643% | $5.78M | 0 | 13 | |
| FOEHR MATTHEW W | director | 132036 0.1143% | $4.02M | 5 | 2 | +1.62% |
| Rowland Charles A Jr | director | 30000 0.026% | $913,500.00 | 1 | 2 | +92.12% |
| Rouan Sarah Kathryn | director | 1240 0.0011% | $37,758.00 | 1 | 3 | |
| LIGAND PHARMACEUTICALS INC | 10 percent owner | 5819383 5.0361% | $177.2M | 0 | 3 | |
| MORNEAU MICHAEL | VP, Finance and Administration | 94035 0.0814% | $2.86M | 0 | 1 | |
| MACARTNEY LAWSON | director | 47965 0.0415% | $1.46M | 1 | 4 | +92.12% |
| SINGLETON J MATTHEW | director | 9500 0.0082% | $289,275.00 | 1 | 5 | <0.0001% |
| Webster Stephen W | director | 8000 0.0069% | $243,600.00 | 1 | 0 | +92.12% |
$159,914,414 | 243 | 18.52% | $4.17B | |
$66,736,176 | 136 | 27.54% | $3.69B | |
$52,263,649 | 70 | 1.18% | $3.8B | |
$11,588,217 | 69 | 42.07% | $3.03B | |
$104,428,685 | 44 | 22.55% | $2.94B | |
$148,770,544 | 34 | 80.63% | $3B | |
$1,275,975,557 | 32 | 19.44% | $3.88B | |
$61,717,660 | 28 | 36.84% | $3.57B | |
$5,066,938 | 27 | 26.38% | $3.22B | |
$150,253,463 | 26 | -52.83% | $3.35B | |
$27,105,902 | 21 | -16.06% | $3.85B | |
$137,061,250 | 16 | 23.01% | $3.26B | |
$92,580,864 | 14 | -1.28% | $3.18B | |
Viking Therapeutics, Inc. (VKTX) | $1,711,150 | 9 | 31.59% | $3.52B |
$182,500,000 | 6 | 29.00% | $4.06B | |
$461,215 | 5 | 10.35% | $4B | |
$142,493,653 | 3 | 4.30% | $3.33B | |
$50,990,767 | 2 | 19.79% | $3.82B | |
$9,900,000 | 1 | -7.19% | $3.01B |
| Increased Positions | 217 | +49.54% | 11M | +14.96% |
| Decreased Positions | 186 | -42.47% | 17M | -22.54% |
| New Positions | 87 | New | 2M | New |
| Sold Out Positions | 54 | Sold Out | 6M | Sold Out |
| Total Postitions | 469 | +7.08% | 71M | -7.58% |
| Vanguard Group Inc | $354,168.00 | 8.85% | 10M | -163,525 | -1.61% | 2025-09-30 |
| Fmr Llc | $205,084.00 | 5.12% | 5.79M | -4M | -41.05% | 2025-09-30 |
| Blackrock, Inc. | $198,216.00 | 4.95% | 5.6M | +158,658 | +2.92% | 2025-09-30 |
| State Street Corp | $159,880.00 | 4% | 4.51M | +738,141 | +19.55% | 2025-09-30 |
| Morgan Stanley | $132,085.00 | 3.3% | 3.73M | +481,423 | +14.82% | 2025-09-30 |
| Jpmorgan Chase & Co | $91,280.00 | 2.28% | 2.58M | -61,968 | -2.35% | 2025-09-30 |
| Susquehanna International Group, Llp | $74,367.00 | 1.86% | 2.1M | +32,913 | +1.59% | 2025-09-30 |
| Ameriprise Financial Inc | $74,128.00 | 1.85% | 2.09M | +616,526 | +41.76% | 2025-09-30 |
| Two Sigma Investments, Lp | $73,868.00 | 1.85% | 2.09M | +771,704 | +58.74% | 2025-09-30 |
| Citadel Advisors Llc | $67,239.00 | 1.68% | 1.9M | +1M | +117.46% | 2025-09-30 |